Subcutaneous Bortezomib in Older Multiple Myeloma Patients (> 75 y/o)

Violeta Martinez Robles,Belen Ballina,Seila Cerda,Paola Gonzalez,Filomeno Rodon,Natalia de las Heras,Jose Antonio Rodríguez-García,Fernando Escalante

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2017）

引用 0|浏览13

暂无评分

摘要

Formulation and administration of subcutaneous Bortezomib (SC-BTZ) has lead to a really important change in Multiple Myeloma's patients management getting to achieve a optimum dose cadence and accumulation without large adverse events, dose reductions or discontinuations, improving this way response rates in comparison with intravenous (i.v.) formulation.

查看译文

关键词

older multiple myeloma patients,multiple myeloma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要